One More Certificate: Syrebo Hand Rehabilitation Robot Achieves TGA Certification in Australia
2024-12-25
IDOPRESS
SHANGHAI,Dec. 24,2024 -- Syrebo,a global leader in rehabilitation robotics,is proud to announce that its Hand Rehabilitation Robot has been granted official certification by the Therapeutic Goods Administration (TGA),marking a significant achievement in the company's mission to advance medical rehabilitation technology.
The Syrebo Hand Rehabilitation Robot is a cutting-edge,robotic-assisted device designed to facilitate the rehabilitation of patients recovering from neurological conditions,hand injuries,or stroke-related impairments. Combined with soft robotic exoskeleton technology and neuroscience,it integrates a variety of training methods,such as passive training,mirror training,active training,etc.,providing patients with effective and convenient solutions to recover hand function.
Achieving TGA certification represents a pivotal milestone for Syrebo and is a testament to the safety,efficacy,and quality of the Hand Rehabilitation Robot. The certification will allow Syrebo to expand its reach in Australia and provide therapists with a innovative tool for enhancing patient care and rehabilitation outcomes. "With Syrebo's successful penetration into the European and U.S. markets,the new TGA certification will further expand our global presence," said Gavin Yin,Founder & CEO of Syrebo. Syrebo plans to collaborate closely with healthcare institutions and rehabilitation centers across Asia-Pacific to integrate their rehabilitation solutions into therapeutic programs.
Syrebo lnnovative Rehabilitation Solutions for Hospitals/Communities/Families
Visit SYREBO on social media:
Facebook: http://www.facebook.com/syrebosiyiintelligence/
LinkedIn: http://www.linkedin.com/company/syrebo
Youtube: http://www.youtube.com/@syrebo
More about SYREBO,please check on the following link
http://www.syrebo.com
info@syrebo.com
Newest
-
Jewellery & Gem ASEAN Bangkok (JGAB) 2025: Connecting ASEAN's Gem and Jewellery Business to the Global Market
-
BioCity Biopharmaceutics Co., Ltd. Announces Clinical Collaboration to Evaluate BC3195 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced or Metastatic Solid Tumors
-
Acer Reports FY2024 Net Income of NT$5.54 Billion and NT$1.7 Cash Dividend Per Share
-
Ping An #1 in Brand Finance's Global Insurance Brand Value for 9th Year, Brand Value Reaches $33.6 Billion